TAKHZYRO® (lanadelumab injection) receives positive recommendation from CADTH’s Canadian Drug Expert Committee (CDEC) for the routine prevention of hereditary angioedema (HAE) attacks
© 2020 Takeda Canada Inc. All rights reserved.
You are about to leave the Takeda Canada website. This link is provided by Takeda as a resource to website visitors. Takeda Canada does not endorse or take responsibility for information presented on any website except its own.
Do you wish to leave this site?